
In clinical studies, a majority of patients on HUMIRA saw symptom relief and many achieved remission (few or no symptoms) at 4 weeks.
% who saw significant SYMPTOM RELIEF
% who achieved REMISSION
People who took HUMIRA
58% & 52%
36% & 21%
People who took placebo
34% & 34%
12% & 7%
HUMIRA is not right for everyone. Only your doctor can decide if HUMIRA is right for you.
HUMIRA has helped many people notice a significant difference in their symptoms in about 4 weeks; however, individual results may vary. Patients who do not see results within 12 weeks should talk to their doctor.

HUMIRA is used in clinical trials for the treatment of adult Crohn’s for the first time*
HUMIRA is used in clinical trials for the treatment of (UC) for the first time†
HUMIRA is approved in the US as a treatment for moderate to severe adult Crohn’s disease
HUMIRA is approved in the US as a treatment for moderate to severe ulcerative colitis
Over one million patients are currently being treated with HUMIRA worldwide.1‡
HUMIRA Citrate-free is approved with less pain immediately following injection§
*First adult Crohn's clinical trial patient dosed in 2002.
†First UC clinical trial patient dosed in 2006.
‡As of June 2016.
§Compared to HUMIRA 40 mg/0.8 mL.
Reference: 1. Data on file, AbbVie Inc. IMS NPA and IMS NSP cumulative data as of June 2016.
HUMIRA is a prescription medicine used in adults to help get moderate to severe ulcerative colitis under control (induce remission) and keep it under control (sustain remission) when certain other medicines have not worked well enough. It is not known if HUMIRA is effective in people who stopped responding to or could not tolerate anti-TNF medicines.
Managing your treatment for a chronic condition can be overwhelming. HUMIRA Complete can help you:
HUMIRA Complete also offers you a personal Nurse Ambassador,II whose first priority will be to help you start and stay on track with your treatment as prescribed.
IINurse Ambassadors do not give medical advice and will direct you to your health care professional for any treatment-related questions, including further referrals.
US-HUM-181266